Related Experiment Video
Updated: Jun 14, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
Published on: August 16, 2024
Statistical characteristics of moxifloxacin-induced QTc effect
Lihan K Yan1, Joanne Zhang, Moh Jee Ng
1Division of Biometrics VI, Office of Biostatistics/Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Abstract:
Moxifloxacin has been the most commonly used positive control in "thorough" QTc (TQT) studies. In a TQT study, the assay sensitivity is often considered to be established if the baseline corrected mean difference in QTc between moxifloxacin and placebo is greater than 5 ms in common practice at one or more prespecified time points and the observed moxifloxacin induced QTc effect over time follows the proper pharmacokinetics profile. To better understand the statistical characteristics of moxifloxacin-induced QTc prolongation and to provide guidance for future studies, 20 TQT studies that involved moxifloxacin have been evaluated. We study the QTc profile of the baseline adjusted mean difference in QTc between moxifloxacin and placebo over time. Zhang (2008) proposed that the moxifloxacin induced QTc effect can be evaluated between 1 and 4 h after a single dose (400 mg) administration near the time (T(max)) of peak concentration instead of all time points (typically 9-12 time points) at which QT was measured for the study drug evaluation. After evaluating 20 TQT studies, we confirm that the maximum moxifloxacin effect occurs in the time window between 1 and 4 h post dose. We also investigate the variability of the data as well as correlations between time points and between regimens. These findings and results can be used as a reference for future studies.
Related Concept Videos
Pharmacodynamic Models: Linear Concentration–Effect Model
Depolarizing Blockers: Pharmocokinetics
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Time Course of Drug Effect
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
